Blaze Bioscience
Seattle, US · Founded 2010 · Delaware corporation · 1 known investors
Biotech
Founders & leadership
HL
Heather L. FranklinDirector
SR
Steven R. DalyExecutive Officer, Director
LR
Ludmila R. LobanovaExecutive Officer
JN
Julia NovakExecutive Officer
LL
Ludmila LobanovaExecutive Officer
JM
James M. OlsonDirector
JO
Jan OhrstromDirector
ME
Mary Ellen HughesDirector
DM
Dennis M MillerExecutive Officer
JC
James C. TowneExecutive Officer, Director
LP
Lawrence Patrick HughesDirector
JK
Jan K. OhrstromDirector
Investors · 1
Competitors · 5
by search overlapPrecision BioSciences13 shared keywordsPrecision BioSciences is a clinical-stage biotechnology company developing genome-editing therapies based on its ARCUS platform. Note: the page content provided contains only a cookie consent notice, so this description reflects the company's known focus rather than the extracted text.
Cowles_Investments_StemCentrx11 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Castle Biosciences10 shared keywordsCastle Biosciences develops genomic tests that provide personalized biological information to inform disease diagnosis, treatment selection, and follow-up care decisions for healthcare providers and patients. The company operates in precision genomics and clinical diagnostics focused on improving patient outcomes.
Life Biosciences9 shared keywordsLongevity company with diversified therapies to extend healthy human lifespan
PatSnap9 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Companies competing with Blaze Bioscience for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$15MraisedOct 2024 · 6 investors · BiotechnologyRule 506(b)
▶$15MraisedOct 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jan K. OhrstromDirector
- Steven R. DalyExecutive Officer, Director
- James C. TowneExecutive Officer, Director
- Lawrence Patrick HughesDirector
- Heather L. FranklinDirector
- Ludmila R. LobanovaExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedOct 2024 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedOct 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jan K. OhrstromDirector
- Heather L. FranklinDirector
- Ludmila R. LobanovaExecutive Officer
- Steven R. DalyExecutive Officer, Director
- James C. TowneExecutive Officer, Director
- Lawrence Patrick HughesDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.1MraisedOct 2024 · 2 investors · BiotechnologyRule 506(b)
▶$8.1MraisedOct 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Heather L. FranklinDirector
- Steven R. DalyExecutive Officer, Director
- Lawrence Patrick HughesDirector
- James C. TowneExecutive Officer, Director
- Ludmila R. LobanovaExecutive Officer
- Jan K. OhrstromDirector
- Offering amount
- $20M
- Amount sold
- $8.1M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedOct 2024 · 3 investors · BiotechnologyRule 506(b)
▶$25MraisedOct 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven R. DalyExecutive Officer, Director
- Heather L. FranklinDirector
- Jan K. OhrstromDirector
- James C. TowneExecutive Officer, Director
- Ludmila R. LobanovaExecutive Officer
- Lawrence Patrick HughesDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.2MraisedApr 2020 · 38 investors · BiotechnologyRule 506(b)
▶$20.2MraisedApr 2020 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Claudia JochheimExecutive Officer
- Jan Koch OhrstromDirector
- Dennis MillerExecutive Officer
- Mary Ellen HughesDirector
- Ludmila LobanovaExecutive Officer
- Heather FranklinExecutive Officer, Director
- James Cameron TowneDirector
- Offering amount
- $25.2M
- Amount sold
- $20.2M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedMay 2018 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedMay 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JAN OHRSTROMDirector
- CLAUDIA JOCHHEIMExecutive Officer
- DENNIS MILLERExecutive Officer
- MARY ELLEN HUGHESDirector
- HEATHER FRANKLINExecutive Officer, Director
- LUDMILA LOBANOVAExecutive Officer
- JAMES C. TOWNEDirector
- Offering amount
- $5M
- Amount sold
- $3M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.1MraisedOct 2017 · 32 investors · BiotechnologyRule 506(b)
▶$16.1MraisedOct 2017 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- LUDMILA LOBANOVAExecutive Officer
- MARY ELLEN HUGHESDirector
- HEATHER FRANKLINExecutive Officer, Director
- JAN OHRSTROMDirector
- JAMES C. TOWNEDirector
- DENNIS MILLERExecutive Officer
- Offering amount
- $18.1M
- Amount sold
- $16.1M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$554KraisedJun 2017 · 5 investors · BiotechnologyRule 506(b)
▶$554KraisedJun 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JAMES C. TOWNEDirector
- MARY ELLEN HUGHESDirector
- LUDMILA LOBANOVAExecutive Officer
- JAN OHRSTROMDirector
- DENNIS MILLERExecutive Officer
- HEATHER FRANKLINExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $554K
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $248.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.